Archive

Neovasc Reducer™ Featured During Therapy Development Program in Coburg and Session at Maria Cecilia Hospital in Cotignola

  - Educational events featuring the Reducer hosted in Germany and Italy -   VANCOUVER, CA, COBURG, DE, and COTIGNOLA, IT, November 22, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and...

Read More

Neovasc Tiara™ Progress Highlighted at PCR London Valves 2019

 NASDAQ, TSX: NVCN   VANCOUVER, November 19, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that...

Read More

Neovasc Reducer™ Featured In FOCUS Magazine

NASDAQ, TSX: NVCN VANCOUVER, CA, and BERLIN, DE, November 26, 2019 – Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of...

Read More

Neovasc Appoints Cardiovascular Industry Veteran Bill Little as Chief Operating Officer

®NASDAQ, TSX: NVCN Vancouver, BC, Nov. 06, 2019  -- Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced the appointment of...

Read More